JP2009502969A5 - - Google Patents

Download PDF

Info

Publication number
JP2009502969A5
JP2009502969A5 JP2008524271A JP2008524271A JP2009502969A5 JP 2009502969 A5 JP2009502969 A5 JP 2009502969A5 JP 2008524271 A JP2008524271 A JP 2008524271A JP 2008524271 A JP2008524271 A JP 2008524271A JP 2009502969 A5 JP2009502969 A5 JP 2009502969A5
Authority
JP
Japan
Prior art keywords
efavirenz
composition
polymer
solvent
solubility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502969A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/029822 external-priority patent/WO2007014393A2/en
Publication of JP2009502969A publication Critical patent/JP2009502969A/ja
Publication of JP2009502969A5 publication Critical patent/JP2009502969A5/ja
Pending legal-status Critical Current

Links

JP2008524271A 2005-07-28 2006-07-28 非晶質エファビレンツ及びその製造 Pending JP2009502969A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70337405P 2005-07-28 2005-07-28
PCT/US2006/029822 WO2007014393A2 (en) 2005-07-28 2006-07-28 Amorphous efavirenz and the production thereof

Publications (2)

Publication Number Publication Date
JP2009502969A JP2009502969A (ja) 2009-01-29
JP2009502969A5 true JP2009502969A5 (OSRAM) 2009-09-10

Family

ID=37450928

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008524271A Pending JP2009502969A (ja) 2005-07-28 2006-07-28 非晶質エファビレンツ及びその製造
JP2008524228A Active JP5243247B2 (ja) 2005-07-28 2006-07-28 スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008524228A Active JP5243247B2 (ja) 2005-07-28 2006-07-28 スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品

Country Status (6)

Country Link
US (2) US10532028B2 (OSRAM)
EP (2) EP1912730A2 (OSRAM)
JP (2) JP2009502969A (OSRAM)
CN (3) CN101272848B (OSRAM)
BR (1) BRPI0614455A2 (OSRAM)
WO (2) WO2007014393A2 (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US8293819B2 (en) * 2006-11-24 2012-10-23 Canon Kabushiki Kaisha Method for producing particles and particles
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
DK2328539T3 (en) * 2008-09-25 2018-06-18 Isp Investments Llc SOFT TABLET COATING COMPOSITION WITH HIGH DRY CONTENT
US11458105B2 (en) 2008-12-04 2022-10-04 International Flavors & Fragrances Inc. Hybrid fragrance encapsulate formulation and method for using the same
KR20110107806A (ko) * 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EP2343056A1 (en) * 2009-12-30 2011-07-13 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Producing stable adefovir dipivoxil solid dispersions
JP2011153119A (ja) * 2010-01-27 2011-08-11 Mylan Seiyaku Ltd バンコマイシンまたはその塩を含有する錠剤
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
SI2609923T1 (sl) 2010-03-31 2017-10-30 Gilead Pharmasset Llc Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
WO2012063498A2 (ja) * 2010-11-12 2012-05-18 富士化学工業株式会社 新規なエキセメスタン固体分散体
ES2836809T3 (es) 2010-11-24 2021-06-28 Melinta Subsidiary Corp Composiciones farmacéuticas
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
EP2661254B1 (en) 2011-01-05 2017-08-02 Hospira, Inc. Spray drying vancomycin
GB201115633D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
RS62676B1 (sr) 2012-09-11 2021-12-31 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
US9114170B2 (en) * 2012-11-08 2015-08-25 Isp Investments Inc. Highly loaded amorphous efavirenz composition and process for preparing the same
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
CN104119209B (zh) * 2013-04-25 2018-03-02 浙江医药股份有限公司新昌制药厂 一种还原型辅酶q10干粉及其组合物以及制备方法
IN2013MU02828A (OSRAM) * 2013-08-29 2015-07-03 Cadila Healthcare Ltd
WO2015077273A1 (en) * 2013-11-22 2015-05-28 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
DK3076947T3 (en) * 2013-12-04 2018-09-17 Hovione Scientia Ltd Contrast agent containing flavor masking formulations
US9320730B2 (en) * 2014-03-13 2016-04-26 Vasilios Voudouris Bendamustine solid dispersions and continuous infusion
PT107568B (pt) * 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
CN105853482A (zh) * 2015-01-21 2016-08-17 熊慧 人参总次苷在制备治疗和/或预防心肌缺血后脂质代谢异常的药物中的应用
EP3103440A1 (en) 2015-06-12 2016-12-14 INDENA S.p.A. Solid dispersions of coenzyme q10
CN110300615B (zh) * 2017-02-09 2023-08-08 Med-El电气医疗器械有限公司 具有地塞米松涂层的可植入电极
EP3579912B1 (en) * 2017-02-09 2022-08-31 MED-EL Elektromedizinische Geraete GmbH Dexamethasone coating for use with electrode carrier
EP3813543A1 (en) * 2018-06-29 2021-05-05 DSM IP Assets B.V. Fast release benzoic acid in feed
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法
WO2024092404A1 (zh) * 2022-10-31 2024-05-10 南京百正生物医药有限公司 哌拉西林他唑巴坦喷雾干燥粉末的工业化生产方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT251459B (de) * 1962-08-13 1967-01-10 Du Pont Verfahren zur Herstellung von brisanten, organischen Sprengstoffen in feinkristalliner Form
GB1201171A (en) * 1967-03-28 1970-08-05 Atomic Energy Authority Uk Improvements in or relating to the production of fine powders
US3981676A (en) * 1970-03-03 1976-09-21 L'oreal Lyophilized dyes and the use thereof to color keratinic fibers
DE2223896A1 (de) * 1972-05-17 1973-11-29 Sanol Arznei Schwarz Gmbh Verfahren zum ueberziehen von feinteiligen arzneimitteln
JPS5313346B2 (OSRAM) * 1974-03-20 1978-05-09
US4956386A (en) * 1980-04-25 1990-09-11 Gist-Brocades N.V. Pharmaceutical compositions and process for their preparation
JPS5836628A (ja) * 1981-08-26 1983-03-03 Ngk Spark Plug Co Ltd 無機質粉体の造粒方法
US4572915A (en) * 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IT1263840B (it) * 1993-03-30 1996-09-04 Giuseppe Furiosi Formulazioni orali di ubidecarenone in forma di capsule
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
CA2190121A1 (en) * 1994-03-15 1995-09-21 Edith Mathiowitz Polymeric gene delivery system
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
ES2237767T3 (es) * 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
WO1997013503A1 (en) 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US6056971A (en) * 1996-07-24 2000-05-02 Biosytes Usa, Inc. Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9819272D0 (en) * 1998-09-03 1998-10-28 Andaris Ltd Microparticles
EP1058539A1 (en) 1999-01-06 2000-12-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
SK8562002A3 (en) * 1999-12-23 2003-10-07 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
US6740338B1 (en) * 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
AU2001280597A1 (en) * 2000-07-17 2002-01-30 Guilford Pharmaceuticals Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
US6579521B2 (en) * 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US6403116B1 (en) * 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6300377B1 (en) * 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
DE60211139T2 (de) * 2001-04-02 2007-03-01 Astrazeneca Ab Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
KR100463167B1 (ko) 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
BR0210520A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
PT1404300E (pt) * 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
US20030044474A1 (en) * 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
JP2004537401A (ja) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
US6723359B2 (en) * 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
EP1448170A4 (en) * 2001-11-27 2010-05-12 Bristol Myers Squibb Co EFAVIRENZ STAMP PREPARATIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
EP1460897A4 (en) * 2001-12-10 2006-09-13 Spherics Inc PROCESSES AND PRODUCTS SUITED TO THE FORMATION AND ISOLATION OF MICROPARTICLES
KR100664822B1 (ko) * 2002-02-01 2007-01-04 화이자 프로덕츠 인코포레이티드 변형된 분무-건조 장치를 이용한 균질한 분무-건조된 고체비결정성 약물 분산액의 제조 방법
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
RU2004123621A (ru) * 2002-02-01 2005-04-10 Пфайзер Продактс Инк. (Us) Лекарственные формы с немедленным высвобождением, содержащие твердые дисперсии лекарств
ES2302913T3 (es) * 2002-02-14 2008-08-01 Dsm Ip Assets B.V. Formulaciones a base de coenzima q-10.
DE10214031A1 (de) * 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
EP1569620A4 (en) * 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
GB2401547B (en) * 2003-05-08 2005-07-20 Nektar Therapeutics Uk Ltd Particulate materials
KR20120080243A (ko) 2003-05-28 2012-07-16 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20050133949A1 (en) * 2003-12-19 2005-06-23 Pragtech, Inc. Polymer solidification and coating process
WO2006082500A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
WO2006134610A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited Efavirenz pharmaceutical composition having enhanced dissolution profile
US20090220596A1 (en) * 2005-07-05 2009-09-03 Abbott Gmbh & Co. Kg Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix
CA2618264C (en) * 2005-08-08 2015-11-24 Abbott Gmbh & Co. Kg Dosage forms with improved bioavailability
SI1978936T1 (sl) * 2006-02-03 2013-10-30 Evonik Roehm Gmbh Farmacevtski sestavki, ki vsebujejo mešanice polimerov in v vodi slabo topna aktivna sredstva
EP2010162A4 (en) * 2006-04-03 2013-01-09 Isa Odidi COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT

Similar Documents

Publication Publication Date Title
JP2009502969A5 (OSRAM)
JP2009502487A5 (OSRAM)
RU2420290C2 (ru) Твердые, пригодные для орального употребления фармацевтические формы применения, содержащие ривароксабан с модифицированным высвобождением
JP2013199488A5 (OSRAM)
JP2009530415A5 (OSRAM)
CN101951891A (zh) 固态药物剂型
JP2763879B2 (ja) 徐放性カプセルもしくは錠剤製剤及びその調製方法
JP2016525527A (ja) 非晶質ダパグリフロジンを含有する製剤
WO2005060940A2 (de) Verfahren zur herstellung einer festen, oral applizierbaren pharmazeutischen zusammensetzung
JP2012509329A5 (OSRAM)
SI23290A (sl) Nove oblike ivabradin hidroklorida
US20130102588A1 (en) Tolvaptan solid dispersion and its preparation method
HK1209337A1 (en) Medicament-containing hollow particle
JP6320371B2 (ja) エンテカビルの医薬組成物および製造方法
JP2017122056A (ja) 医薬含有造粒物の製造方法
JP2009502968A5 (OSRAM)
JPH10152440A (ja) 活性物質としてニフェジピンを含有する経口投与用調節放出医薬組成物
JP3786287B2 (ja) 塩酸ベニジピン含有医薬組成物
WO2014193528A1 (en) Amorphous dosage forms and methods
JP5103173B2 (ja) ジヒドロピリジン系化合物の分解を防止する方法
JP4606258B2 (ja) 塩酸ベニジピン含有医薬組成物
JPS5883617A (ja) ジヒドロピリジンを含有する固体の迅速放出性薬剤調製物及びその製造方法
WO2009123169A1 (ja) アミド誘導体含有医薬組成物
JP7407364B2 (ja) ラメルテオン含有固形製剤
JP6072705B2 (ja) 固体分散体製剤